Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias

Marius M. Hoeper, Juergen Behr, Matthias Held, Ekkehard Grunig, C. Dario Vizza, Anton Vonk-Noordegraaf, Tobias J. Lange, Martin Claussen, Christian Grohé, Hans Klose, Karen M. Olsson, Thomas Zelniker, Claus Neurohr, Oliver Distler, Hubert Wirtz, Christian Opitz, Doerte Huscher, David Pittrow, J. Simon R Gibbs

Research output: Contribution to journalArticle

Abstract

Background: Pulmonary hypertension (PH) is a common finding in patients with chronic fibrosing idiopathic interstitial pneumonias (IIP). Little is known about the response to pulmonary vasodilator therapy in this patient population. COMPERA is an international registry that prospectively captures data from patients with various forms of PH receiving pulmonary vasodilator therapies. Methods: We retrieved data from COMPERA to compare patient characteristics, treatment patterns, response to therapy and survival in newly diagnosed patients with idiopathic pulmonary arterial hypertension (IPAH) and PH associated with IIP (PH-IIP). Results: Compared to patients with IPAH (n = 798), patients with PH-IIP (n = 151) were older and predominantly males. Patients with PH-IIP were treated predominantly with phosphodiesterase-5 inhibitors (88% at entry, 87% after 1 year). From baseline to the first follow-up visit, the median improvement in 6MWD was 30 m in patients with IPAH and 24.5 m in patients with PH-IIP (p = 0.457 for the difference between both groups). Improvements in NYHA functional class were observed in 22.4% and 29.5% of these patients, respectively (p = 0.179 for the difference between both groups). Survival rates were significantly worse in PH-IIP than in IPAH (3-year survival 34.0 versus 68.6%; p

Original languageEnglish
Article numbere0141911
JournalPLoS One
Volume10
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Idiopathic Interstitial Pneumonias
Vasodilator Agents
Pulmonary Hypertension
pneumonia
hypertension
lungs
Phosphodiesterase 5 Inhibitors
Data acquisition
vasodilator agents
therapeutics
Lung
Survival
Therapeutics
Registries

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Hoeper, M. M., Behr, J., Held, M., Grunig, E., Vizza, C. D., Vonk-Noordegraaf, A., ... Gibbs, J. S. R. (2015). Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias. PLoS One, 10(12), [e0141911]. https://doi.org/10.1371/journal.pone.0141911

Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias. / Hoeper, Marius M.; Behr, Juergen; Held, Matthias; Grunig, Ekkehard; Vizza, C. Dario; Vonk-Noordegraaf, Anton; Lange, Tobias J.; Claussen, Martin; Grohé, Christian; Klose, Hans; Olsson, Karen M.; Zelniker, Thomas; Neurohr, Claus; Distler, Oliver; Wirtz, Hubert; Opitz, Christian; Huscher, Doerte; Pittrow, David; Gibbs, J. Simon R.

In: PLoS One, Vol. 10, No. 12, e0141911, 01.12.2015.

Research output: Contribution to journalArticle

Hoeper, MM, Behr, J, Held, M, Grunig, E, Vizza, CD, Vonk-Noordegraaf, A, Lange, TJ, Claussen, M, Grohé, C, Klose, H, Olsson, KM, Zelniker, T, Neurohr, C, Distler, O, Wirtz, H, Opitz, C, Huscher, D, Pittrow, D & Gibbs, JSR 2015, 'Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias', PLoS One, vol. 10, no. 12, e0141911. https://doi.org/10.1371/journal.pone.0141911
Hoeper MM, Behr J, Held M, Grunig E, Vizza CD, Vonk-Noordegraaf A et al. Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias. PLoS One. 2015 Dec 1;10(12). e0141911. https://doi.org/10.1371/journal.pone.0141911
Hoeper, Marius M. ; Behr, Juergen ; Held, Matthias ; Grunig, Ekkehard ; Vizza, C. Dario ; Vonk-Noordegraaf, Anton ; Lange, Tobias J. ; Claussen, Martin ; Grohé, Christian ; Klose, Hans ; Olsson, Karen M. ; Zelniker, Thomas ; Neurohr, Claus ; Distler, Oliver ; Wirtz, Hubert ; Opitz, Christian ; Huscher, Doerte ; Pittrow, David ; Gibbs, J. Simon R. / Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias. In: PLoS One. 2015 ; Vol. 10, No. 12.
@article{c023c6875a8943d495bb80b533060acc,
title = "Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias",
abstract = "Background: Pulmonary hypertension (PH) is a common finding in patients with chronic fibrosing idiopathic interstitial pneumonias (IIP). Little is known about the response to pulmonary vasodilator therapy in this patient population. COMPERA is an international registry that prospectively captures data from patients with various forms of PH receiving pulmonary vasodilator therapies. Methods: We retrieved data from COMPERA to compare patient characteristics, treatment patterns, response to therapy and survival in newly diagnosed patients with idiopathic pulmonary arterial hypertension (IPAH) and PH associated with IIP (PH-IIP). Results: Compared to patients with IPAH (n = 798), patients with PH-IIP (n = 151) were older and predominantly males. Patients with PH-IIP were treated predominantly with phosphodiesterase-5 inhibitors (88{\%} at entry, 87{\%} after 1 year). From baseline to the first follow-up visit, the median improvement in 6MWD was 30 m in patients with IPAH and 24.5 m in patients with PH-IIP (p = 0.457 for the difference between both groups). Improvements in NYHA functional class were observed in 22.4{\%} and 29.5{\%} of these patients, respectively (p = 0.179 for the difference between both groups). Survival rates were significantly worse in PH-IIP than in IPAH (3-year survival 34.0 versus 68.6{\%}; p",
author = "Hoeper, {Marius M.} and Juergen Behr and Matthias Held and Ekkehard Grunig and Vizza, {C. Dario} and Anton Vonk-Noordegraaf and Lange, {Tobias J.} and Martin Claussen and Christian Groh{\'e} and Hans Klose and Olsson, {Karen M.} and Thomas Zelniker and Claus Neurohr and Oliver Distler and Hubert Wirtz and Christian Opitz and Doerte Huscher and David Pittrow and Gibbs, {J. Simon R}",
year = "2015",
month = "12",
day = "1",
doi = "10.1371/journal.pone.0141911",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias

AU - Hoeper, Marius M.

AU - Behr, Juergen

AU - Held, Matthias

AU - Grunig, Ekkehard

AU - Vizza, C. Dario

AU - Vonk-Noordegraaf, Anton

AU - Lange, Tobias J.

AU - Claussen, Martin

AU - Grohé, Christian

AU - Klose, Hans

AU - Olsson, Karen M.

AU - Zelniker, Thomas

AU - Neurohr, Claus

AU - Distler, Oliver

AU - Wirtz, Hubert

AU - Opitz, Christian

AU - Huscher, Doerte

AU - Pittrow, David

AU - Gibbs, J. Simon R

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: Pulmonary hypertension (PH) is a common finding in patients with chronic fibrosing idiopathic interstitial pneumonias (IIP). Little is known about the response to pulmonary vasodilator therapy in this patient population. COMPERA is an international registry that prospectively captures data from patients with various forms of PH receiving pulmonary vasodilator therapies. Methods: We retrieved data from COMPERA to compare patient characteristics, treatment patterns, response to therapy and survival in newly diagnosed patients with idiopathic pulmonary arterial hypertension (IPAH) and PH associated with IIP (PH-IIP). Results: Compared to patients with IPAH (n = 798), patients with PH-IIP (n = 151) were older and predominantly males. Patients with PH-IIP were treated predominantly with phosphodiesterase-5 inhibitors (88% at entry, 87% after 1 year). From baseline to the first follow-up visit, the median improvement in 6MWD was 30 m in patients with IPAH and 24.5 m in patients with PH-IIP (p = 0.457 for the difference between both groups). Improvements in NYHA functional class were observed in 22.4% and 29.5% of these patients, respectively (p = 0.179 for the difference between both groups). Survival rates were significantly worse in PH-IIP than in IPAH (3-year survival 34.0 versus 68.6%; p

AB - Background: Pulmonary hypertension (PH) is a common finding in patients with chronic fibrosing idiopathic interstitial pneumonias (IIP). Little is known about the response to pulmonary vasodilator therapy in this patient population. COMPERA is an international registry that prospectively captures data from patients with various forms of PH receiving pulmonary vasodilator therapies. Methods: We retrieved data from COMPERA to compare patient characteristics, treatment patterns, response to therapy and survival in newly diagnosed patients with idiopathic pulmonary arterial hypertension (IPAH) and PH associated with IIP (PH-IIP). Results: Compared to patients with IPAH (n = 798), patients with PH-IIP (n = 151) were older and predominantly males. Patients with PH-IIP were treated predominantly with phosphodiesterase-5 inhibitors (88% at entry, 87% after 1 year). From baseline to the first follow-up visit, the median improvement in 6MWD was 30 m in patients with IPAH and 24.5 m in patients with PH-IIP (p = 0.457 for the difference between both groups). Improvements in NYHA functional class were observed in 22.4% and 29.5% of these patients, respectively (p = 0.179 for the difference between both groups). Survival rates were significantly worse in PH-IIP than in IPAH (3-year survival 34.0 versus 68.6%; p

UR - http://www.scopus.com/inward/record.url?scp=84956660431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956660431&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0141911

DO - 10.1371/journal.pone.0141911

M3 - Article

AN - SCOPUS:84956660431

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e0141911

ER -